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Background: In the Netherlands, disease management programs (DMPs) are used to treat chronic diseases. Their
aim is to improve care and to control the rising expenditures related to chronic diseases. A bundled payment was
introduced to facilitate the implementation of DMPs. This payment is an all-inclusive price per patient per year for a
pre-specified care package. However, it is unclear to which extent the costs of developing and implementing DMPs are
included in this price. Consequently, the organizations providing DMPs bear financial risk because the development
and implementation (D&I) costs may be substantial. The aim of this paper is to investigate the variability in and drivers
of D&I costs among 22 DMPs and highlight characteristics that impact these.
Methods: The data was analyzed using a mixed methods approach. Descriptive statistical analysis explored the
variability in D&I costs as measured by a self-developed costing instrument and investigated the drivers. In addition,
qualitative research, including document analysis and interviews, was conducted to explain the possible underlying
reasons of cost variability.
Results: The development costs varied from €5,891 to €274,783 and the implementation costs varied from €7,278
to €387,879 across DMPs. Personnel costs were the main component of development. Development costs were
strongly correlated with the implementation costs (ρ = 0.55), development duration (ρ = 0.74), and number of FTEs
dedicated DMP development. Organizations with large size and high level of care prior to the implementation of a
DMP had relatively low development costs. These findings were in line with the cross-case qualitative comparison
where programs with a longer history, more experienced project leadership, previously established ICT systems, and
less complex patient populations had lower D&I costs.
Conclusions: There is wide variation in D&I costs of DMPs, which is driven primarily by the duration of the
development phase and the staff needed to develop and implement a DMP. These drivers are influenced by the
attributes of the DMP, characteristics of the target population, project leadership, and ICT involved. There are
indications of economies of scale and economies of scope, which may reduce D&I costs.
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In recent years, the healthcare community has been
struggling to identify strategies to better manage the
rise in the number of patients with chronic diseases. In
the Netherlands, there has been a 17% growth in diag-
noses of chronic disease and a 26% growth of patients
with multiple chronic disease diagnoses in the past
8 years [1]. One possible method of managing the
changes in healthcare that result from the increased
diagnosis of chronic diseases is the D&I of disease man-
agement programs (DMPs), as has happened in the
Netherlands. The Netherlands Organization for Health
Research and Development (Nederlandse Organisatie voor
Gezondheidsonderzoek en Zorginnovatie (ZonMw)) funded
a research project to stimulate the implementation of DMPs
and study their impact. Twenty-two healthcare delivery sites
were awarded funding to participate in the study by devel-
oping and implementing a DMP; the majority of the sites
were primary care cooperatives. In exchange for funding
and support, each of the sites agreed to participate in re-
search and put a DMP into place. Disease management was
defined by the funding organization as:
a broad programmatic approach to chronic diseases,
and a comprehensive care chain of diagnosis,
treatment and counseling, as well as prevention, early
detection and self-management. The approach is
based on multidisciplinary care standards and is
organized around the patient and his condition, as
much as possible, in conjunction with his surroundings.
(Call for proposals, page 7)
In the programs proposed by the care delivery organi-
zations and in the literature about DMPs, patients’ par-
ticipation in the treatment and management of their
condition is a key component of DMPs [2], as is the in-
volvement of multiple medical professionals in care
planning and delivery [3], and the development and im-
plementation of information systems (most frequently
computer-based systems) to support chronic disease
treatment and management [4]. The development of the
DMPs at the selected sites included interventions altering
the existing organization of healthcare delivery (e.g. regu-
lar multidisciplinary meetings and regular monitoring of
patients) and interventions that were implemented as new
processes (e.g. case management, self-management sup-
port, ICT). A more detailed description of the interven-
tions is given in elsewhere [5].
In addition to funding for research on DMPs, the
Netherlands has implemented a new financing system
that impacted care for those with common chronic dis-
eases (an overview of the Dutch healthcare system is
provided in Additional file 1). In 2010, a bundled pay-
ment scheme was introduced in the Netherlands [6].Bundled payment is a single payment that covers the
multidisciplinary care required by a patient for one par-
ticular chronic disease during a predefined period of
time [7]. The aim of this payment scheme was to im-
prove the access, comprehensiveness, continuity, and
other aspects of quality of care for chronic patients and
to control the increasing expenditures for healthcare for
patients with a chronic disease. In the first year of this
funding reform, only care for diabetes mellitus (DM),
chronic obstructive pulmonary disease (COPD), and car-
diovascular risk (CVR) could be contracted in a bundled
payment. Under the new payment scheme, chronic care is
coordinated by groups of healthcare providers (called ‘care
groups’). The bundled payment is negotiated between care
groups and health insurers and includes 1) the costs of
multiple caregivers in primary care (e.g. general practi-
tioners, practice nurses, dieticians, physiotherapists, life-
style counselor but not medicines, diagnostics and
medical devices) as well as 2) the costs of care coordin-
ation, 3) information and communication technology
(ICT), and 4) professional training and courses for health-
care providers. The latter three groups of costs can be
seen as costs for the development and implementation
(D&I) of DMPs.
Since DMPs involve a significant reorganization of
healthcare delivery, they require substantial development
costs (including but not limited to training costs, ICT
costs, and costs of redesigning the care delivery process)
and implementation costs (such as multidisciplinary team
meetings, the costs of coordination between care-givers,
the costs of monitoring and feedback). These costs are
commonly carried by the organization that implements the
program (i.e. care groups). To which extent the D&I costs
of DMPs are included in the bundled payment is often un-
clear. This is despite recommendations to report these
costs separately from the healthcare utilization costs and to
include them in the price of implementing a DMP [8].
However, some insurers, including the largest one in
the Netherlands, are not convinced about the benefits
of bundled payment and do not provide this type of
funding. Rather, these health insurers provide an add-
on payment to cover the D&I costs, whereas the cost
of healthcare is funded as before. It is not clear how
this add-on payment is defined and to what extent it
covers the D&I costs [9]. Considering this uncertainty
and taking into account the substantial D&I costs of a
DMP, care groups need to be able to correctly antici-
pate the D&I costs. Failing to do so could be financially
disastrous for the providers of DMPs and serves as a
disincentive for the implementation of DMPs.
The aim of this paper is to investigate the variability
in and drivers of D&I costs among various DMPs and
highlight characteristics of the DMPs that may explain
the variability in costs during the project period.
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The research for this paper was conducted as part of an
evaluation of 22 Dutch DMPs spread across different re-
gions of the Netherlands [5]. The DMPs were categorized
in CVR (n = 9), COPD (n = 4), DM (n = 3), mental diseases
(n = 3), and other (n = 3). The ‘other’ disease category
includes DMPs for stroke, heart failure, and mix of
CVR, COPD and DM. The Ethics Board of Erasmus
University approved the data collection. All content has
been anonymized.
Methods
We used a mixed-methods approach to analyze data on
D&I costs. To this end, we used descriptive statistical
analysis to explore the variability in D&I costs, as well
document analysis and interviews with project leaders,
managers, and professional care givers.Quantitative methods
All development and implementation costs associated
with the 22 DMPs were systematically collected. We de-
veloped a template that was based on the CostIt instru-
ment of the World Health Organization (WHO) [10].
This template was completed during face-to-face inter-
views with DMP managers. During these interviews we
also asked managers whether they had additional finan-
cing to cover the specific elements of disease manage-
ment. The development costs included all costs made
during the preparation phase of DMPs, e.g. labor costs
for brainstorming sessions, training costs, and ICT sup-
port costs. The implementation costs included costs of
multidisciplinary team meetings, coordination between
care-givers, monitoring and feedback that occurred the
year after the DMP implementation. We collected the
development and implementation costs regardless of the
budget holder for their financing; the budget holders
could include care groups, health insurers, and/or gov-
ernment. The labor costs were calculated using the full-
time equivalents (FTEs), duration of involvement in the
project and the gross salary of medical, administrative,
ICT, management and other personnel. Operating costs
(including costs of professional courses, information/
communication, licenses, and materials) were calculated
based on volumes and unit prices as stated in the tem-
plate. Capital costs (such as building and purchase of
ICT) were calculated based on their volume (for build-
ings that was square meters) and unit prices (for build-
ings that was Euro per square meter) and they were
amortized over their lifespan as suggested by the WHO
[10]. In the analysis, we included the development costs
during the development phase, the annualized develop-
ment costs, and the implementation costs in the year
after implementation.In addition to D&I costs, we also collected data about
the duration of the development phase (in months), the
number of patients participating in a DMP, the total
FTEs available to the organization providing a DMP,
and the FTEs dedicated to developing and implement-
ing the DMP. The level of chronic care integration was
also measured at the start of providing a DMP and a
year later by using the Dutch translation of the Patient
Assessment of Chronic Illness Care (PACIC) [11]. This
questionnaire was distributed to participants of 19
DMPs (no data for the 3 mental disease DMPs was
available). The mean PACIC value of the participants in
each DMP was used in the analysis.
Descriptive statistics were used to investigate the vari-
ability in D&I costs among 22 DMPs. Pearson correlation
coefficients and Spearman correlation coefficients were cal-
culated for normally distributed and non-normally distrib-
uted variables, respectively. The normality was tested
based on the Kolmogorov-Smirnoff test. We also per-
formed an analysis of variance based on ANOVA and
Kruskal-Wallis estimates to explore differences in the
development and implementation costs among disease
categories. We also performed an analysis of variance to
investigate differences in D&I costs among different
payment methods during the development and imple-
mentation phases. The payments were categorized in
normal (e.g. for GPs this is a mixture of fee-for-service
and capitation payment), normal plus add-on payment
for D&I costs, and bundled payment. Considering the
small number of observations (n = 22) we also looked
into various associations using scatter plots and graphs.
Qualitative methods
In order to understand how various characteristics may in-
fluence the costs associated with the D&I of DMPs, we ex-
amined how program plans ‘travel’ from the grant proposal
to the D&I of the DMPs [9], as well as what actually hap-
pened during the D&I phases of the program by exploring
and analyzing the multiplicity of D&I in practice [12]. This
approach enabled us to gain a deeper knowledge of the ac-
tivities implicit in DMPs, including activities that influence
how programs develop, how programs use the provided fi-
nances, and how project teams overcame (or not) difficul-
ties in the early stages of programs.
Document analysis was the first step of the qualitative
data collection. The documents analyzed included the
grant applications and project plans submitted by pro-
ject leaders, the call for proposals (Diseasemanagement
chronische ziekten), and care organization websites. The
documents were analyzed inductively to gain a better
understanding of the DMPs, project leaders, and care
providers. The content of the documents informed the
development of the interview guide, which focused on
D&I of DMPs in practice.
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which highlight the different D&I costs in the DMPs; 15
interviews with project leaders and clinicians were con-
ducted and used in the case studies presented in this
manuscript. Questions about the history and contexts of
the DMPs were asked. Interviews were digitally recorded
and detailed notes and observations were also made dur-
ing the interviews. Interviews were conducted in Dutch
or English and ranged from 30 minutes to 90 minutes.
Interviews were transcribed and coded into themes.
Quotes were translated by a native English speaker; the
translations were later confirmed by a native Dutch
speaker.
To better understand the variability in costs from a
mixed methods perspective, the primary economic re-
searcher (AT) and the primary qualitative researcher
(BHW) met regularly and jointly reviewed the data. The
economic and qualitative data have been integrated it-
eratively, after consensus by all authors. This was done
through frequent meetings between the first two authors
and the rest of the authorship team.
Ethics statement
The study protocol was approved by the ethics committee
of the Erasmus University Medical Centre of Rotterdam
(September 2009). For more details see Lemmens et al.,
2011 [5].
Results
Adequate understanding of complex policy structures
and the impact of their change requires multiple types
of information. Mixed-methods research facilitates this
by combining qualitative and quantitative research methods
in order to identify, decompose, analyze, and understand
complexities in healthcare [13]. Our research found a large
variability in D&I costs between the researched DMPs. We
uncovered three common characteristics of the studied
DMPs that may explain the variability in costs between pro-
grams. These characteristics include attributes of the inter-
ventions, ICT systems, and the experience of the project
leaders. The history of the programs, including personnel
time invested and ICT systems already in place, may also
play an important role in the variability in costs and is an
underlying characteristic.
Variability in D&I costs and cost drivers
As Figure 1 shows, the development costs varied from
€5,891 to €274,783 across DMPs and the implementa-
tion costs varied from €7,278 to €387,879 across DMPs.
There was also large variation in D&I costs across
DMPs in the same disease category. In some cases the
development costs were higher than the implementa-
tion costs and in some other cases not. In addition, the
four DMPs with the highest development costs amongall DMPs also had the highest implementation costs.
When annualized, the development costs varied also
largely between and within disease categories and were
also positively associated with the implementation costs.
Personnel costs were the primary component of devel-
opment costs across 18 of 22 DMPs, accounting for
more than 60% of total development costs (Figure 2).
They were followed by ICT costs (maintenance and li-
censing) and the costs of professional courses as the
main cost components of development costs.
The results from the descriptive statistical analysis are
presented in Table 1. This table shows that our sample
consisted of DMPs varying in the duration of the devel-
opment phase (range: 3; 25 months), number of patients
participating in the DMP (range 75; 3,400), total number
of FTEs in an organization (range 1; 2,850), and number
of FTEs involved in developing a DMP (range: 0.1; 2.5).
The mean development costs were €75,832, the mean an-
nualized development costs were €69,749 and the mean
implementation costs were €100,827 across all 22 DMPs.
The mean PACIC at implementation was 2.88 and a year
later was 2.95. The Kolmogorov-Smirnoff test showed that
the variables ‘number of DMP participants, ‘organization
FTEs’, ‘development costs’ and ‘PACIC at implementation’
and ‘PACIC a year later’ were not normally distributed.
The correlations between the D&I costs and potential
cost drivers are presented in Table 2. Total development
costs were strongly correlated with implementation costs
(ρ = 0.55), development duration (ρ = 0.74), and number of
FTEs dedicated to the development of a DMP (ρ = 0.54).
The latter was found to be correlated also with the develop-
ment duration (ρ = 0.49). The annualized development
costs were correlated with the implementation costs (ρ =
0.65) and number of FTEs for the development of a DMP
(ρ = 0.52). The results also showed a negative correlation
between PACIC a year after implementation and develop-
ment (ρ = −0.27) and implementation (ρ = −0.24) costs.
The relation between development costs and the total
number of FTEs in the organization that provides a
DMP is illustrated in Figure 3. This figure shows that
large organizations had relatively low development costs
compared to small organizations. This relation remained
between the annualized development costs and the total
number of FTEs in the organization that provides a DMP
(see Additional file 2: Figure S4).
Figure 4 illustrates the relation between implementa-
tion costs and the number of patients participating in a
DMP. We see that there might be a small negative rela-
tion between the two variables.
The results of the analysis of variance of D&I costs
comparing different payment methods as well as differ-
ent disease categories were not statistically significant.
Figures illustrating these variances are presented in
Additional file 2.
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Figure 1 Development and implementation costs per DMP.
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While each of the practice sites had a different method
of addressing chronic disease through the funded DMP,
the qualitative research uncovered characteristics that help
to understand the differences in D&I costs. These charac-
teristics include attributes of the DMP, ICT systems, and
the experience of the project leadership teams. Qualitative
data from two case studies will illustrate these characteris-
tics. The diabetes case (DMP number 17) had relatively
low D&I costs, while the CVRM case (DMP number 10)
had high D&I costs.
Case study: Diabetes (DMP number 17)
One of the project sites with a focus on adult-onset dia-
betes developed a DMP for clinicians and patients. The
clinicians and project leaders at the site have invested
time and effort in improving diabetes care for patients
since 1999 by working in cooperation with the hospital
and specialists, developing care protocols, and contract-
ing with providers. Around 2006, the changes in diabetes
care were formalised into an early form of disease man-
agement. The studied program was a continuation of a
previously funded program. This site had two project0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Figure 2 Share of total development costs per cost component.leaders, the first of which was hired for the previously
funded program to assist with the development of an elec-
tronic medical record and stayed on through most of the
funded DMP. The first project leader was a professional
healthcare consultant with a background in economics.
The second (and current) project leader was the assistant of
the first and took over the project leadership when the first
project leader left, after a period of mentored transition.
Program attributes
For the disease management study, the project leaders
worked with healthcare professionals to change how
they thought about care and creating multidisciplinary
care teams, implemented an updated networked elec-
tronic medical record system with a patient portal, and
oversaw self-management education for patients.
The multidisciplinary care teams included nurse special-
ists, dieticians, general practitioners, nurses, chronic dis-
ease specialist assistants, ophthalmologists, podiatrists,
and/or internists; members of the care team were located
in multiple GP and specialist offices throughout the re-
gion. The care team worked together, communicating with
each other frequently.
Table 1 Descriptive statistics
Mean SD Median Min Max IQR
Development duration (months) 12 6 12 3 25 6
Patients participating in DMP# 801 986 300 75 3,400 957
Organization FTEs# 433 841 33 1 2,850 256
DMP FTEs 0.76 0.58 0.60 0.10 2.50 0.63
Development costs# 75,832 72,727 49,972 5,891 274,783 85,917
Annualized development costs 69,749 47,807 48,141 7,855 198,188 66,704
Implementation costs 100,827 86,776 74,836 7,278 387,879 117,079
PACIC at baseline# (1–5 best) 2.88 0.29 2.81 2.25 3.60 0.35
PACIC at year 1# (1–5 best) 2.95 0.28 2.99 2.44 3.62 0.40
#The Kolmogorov-Smirnoff test rejected the assumption of normally distributed data; SD: standard deviation; min: minimum; max: maximum; IQR: interquartile
range (Quartile 3-Quartile 1); FTE: full-time equivalent; implementation costs accrued within the first calendar year of DMP implementation.
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especially… We sit together, we discuss a lot, and we
can call the GP or practice nurse, and yes, several
people are looking [at the case]. (Interview with
diabetes specialist nurse)
Communication was seen as key to coordinating care.
It was common for the staff, such as doctors, nurses, di-
eticians, and other clinical professionals, of disease man-
agement teams to sit together in a shared office and
communicate about patients and care; however, this was
not the only way that communication happened. The
diabetes program had regular meetings with clinical pro-
fessionals from multiples GP offices with the project
leader overseeing the meetings. The project leader also
sent out emails, reports, and posted information about
the DMP online. Clinicians also communicated with one
another through the networked electronic medical rec-
ord. This system of coordinated care has been developed
by investing in time for the project leader and clinician
stakeholders over the years of the program.
One of the efforts of this disease management project
focused on self-management through educating patients
about diabetes. There were a variety of formal and infor-
mal educational opportunities for patients: group classes,
clinical visits, and online. Patients could participate in
voluntary classes, which were led by a nurse, doctor,
and/or non-physician chronic disease specialist assistant.
Clinicians were trained to lead by experts in diabetes
education, an additional D&I cost-item which was hoped
to be recouped in a reduced need for individual educa-
tion sessions with patients. However, the classes were no
longer offered as a result of lack of patient interest and
attendance.
Internet-based communication systems
For the diabetes project, as is the case for many medical
practices, the full development and use of an electronic
medical record (EMR) was a complicated process. TheGP offices involved in the diabetes project began work-
ing with software developers in 2006 to develop a more-
limited version of an EMR. The project leaders, espe-
cially the first project leader, worked with clinicians and
software developers to enhance the record. The newly
enhanced record allowed for viewing the record by mul-
tiple clinicians (and the project leaders) at different
physical locations, electronic referrals, and messaging
between clinicians and between clinicians and patients.
Internet-based communication (ICT) systems, such as
the EMR, have been seen as a remedy for the many pre-
dicaments in healthcare delivery and quality, one that
promises more than is realized in most cases [14]. The
implementation of ICT systems in healthcare delivery
has been a lengthy process for project leaders and clini-
cians involved in the DMP, requiring planning, develop-
ing, implementing, and tailoring the system before the
system can begin to meet the needs of clinicians and pa-
tients. At this site, the development of the ICT system
began well before the program was funded as part of the
study. By working with a previously developed system,
this project leader and leadership team had the oppor-
tunity to gain the needed support from stakeholders, as
well as work through the inevitable bugs and challenges
in the system before the funded DMP officially began.
These challenges included:
The fact that the software builder couldn’t deliver
what they said they would deliver. And still now we do
not really have the perfect system and the perfect
system does not exist, I know. But there are too many
things that we want. But, there is no other software
builder at this moment that DOES have it. The
software builder itself has been in bankruptcy 2 times,
once in 2007 and 2 months ago for the second time.
Fortunately they worked together with another
department who had been able to go on with the
system, so that we were not cut off. (Interview 1 with
project leader 1)
Table 2 Correlation coefficients
Development costs Annualized
development
costs
Implementation costs Development duration DMP participants Organization FTE’s DMP FTE’s PACIC baseline PACIC
year 1
Development costs 1
Annualized development
costs
0.79 (0.000) 1
Implementation costs 0.55 (0.008) 0.65 (0.001)# 1
Development duration 0.74 (0.000) 0.24 (0.284)# 0.27 (0.228)# 1
DMP participants −0.12 (0.600) 0.02 (0.922) −0.08 (0.707) −0.09 (0.688) 1
Organization FTE’s −0.03 (0.887) 0.02 (0.940) −0.00 (0.988) −0.03 (0.880) −0.14 (0.549) 1
DMP FTE’s 0.54 (0.010) 0.52 (0.013)# 0.16 (0.482)# 0.49 (0.022)# −0.04 (0.869) −0.35 (0.110) 1
PACIC baseline −0.22 (0.366) −0.02 (0.937) −0.21 (0.388) −0.24 (0.323) 0.21 (0.380) −0.40 (0.095) −0.29 (0.232) 1
PACIC year 1 −0.27 (0.051) −0.08 (0.049) −0.24 (0.044) −0.21 (0.396) −0.23 (0.350) −0.02 (0.932) −0.28 (0.909) 0.64 (0.003) 1
#Based on Pearson correlations; FTE: full-time equivalent; in brackets are the p values of the correlation.
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time and the hurdles that frequently occur in the early
development phases of a networked electronic medical
record occurred, in part, before the study and in the
early phases of the study. Since the computer program
had already been chosen, the time and effort needed to
select a computer program and coordinate the pro-
gram with existing record systems were not part of the
study. As a result, much of the development work and
growing pains of implementing an ICT system were
not seen in the D&I costs for this aspect of the DMP.
One of the goals of the funded portion of the DMP
was the D&I of a patient portal for the networked elec-
tronic medical record. While the project team was able
to develop a patient portal in a timely manner, the devel-
opment of the portal does not guarantee usage.
Yes, we do have that but no-one uses it. We have talked
and talked to get people to look, [telling patients] you
have your own care dossier, your own plan, we can agree
on goals there, you can report on how it is going, you can0
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Figure 4 Association between implementation costs and number of palso tell us what does not go well, or if you have
questions. Really easy, you can do that from your chair
at home, you don’t have to come here if you don’t want
to. But people don’t want that. It has cost money,
because in order to offer the portal we had to expand
our software package. Of the current 2700 people with
diabetes I believe 15 now have a care plan. (Interview 1
with second project leader, diabetes project)
While rates of patient participation in the portal
were low, the numbers were expected to increase in
the future as more internet-friendly patients are diag-
nosed. Though the usage remains low, this D&I cost is
expected to have lasting impact well after the project
period.
The networked electronic medical record has trav-
elled from plan to action successfully in principle, in
that the portal was developed in a timely and cost-
effective manner, but not in the current day-to-day real-
ity of the program, as very few patients used the portal
at the time of the interview. This investment in future2,000 2,500 3,000 3,500 4,000
ed patients
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COPD.2 COPD.3 Multi.1 COPD.4
atients participating in a DMP.
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While the patient portal was successfully developed
from a technical point of view, the implementation in
practice will still require much effort on the part of the
clinician, the project leader, and the expected future
patients, who too must learn how to use the new sys-
tem and whose time is frequently overlooked in ac-
countings of D&I costs.
Project leadership
The cooperation hired an experienced project leader to
oversee the diabetes DMP. Much like the groundwork
done with the ICT system, the hiring of this first project
leader occurred before the funding of the study. The
project leader saw her role as giving support, both ma-
terial and strategic:
And I think that a unique thing is that what I do is
I’m able to give support on the strategic thinking…
where do you want to go to, what are the goals, what’s
your mission, what’s the gain of it. And the second is
how can we achieve that. So it’s not a consultant with
only the advice but also what does it take to get there.
(Interview 1 with project leader 1)
The first and second project leaders led meetings, cre-
ated reports from data extracted from the networked
electronic medical record, and coordinated the efforts
of the study team, such as sending out surveys. When
the project leader resigned, she passed the role on to
her assistant.
Effective leadership is crucial for bringing projects to
life. In fact, in their seminal article on DMPs, Wagner
et al. [3] point out that making the change needed for
DMPs is “difficult, if not impossible, without strong
leadership”. Leadership support was (and, in general,
is) needed for multiple aspects of the DMP: for the
successful implementation of a health ICT system
[15], to guide the vision of the improvements in
chronic care treatment and management [2,16], and to
facilitate change in the healthcare delivery [17]. Yet
project leadership skills and efficiency grow over time,
as the project leader gains the trust of the clinicians,
as the project leader is better able to understand the
needs of the clinicians and patients, and as the project
leader and the clinicians are able to adapt to one
another.
Case study: Risk of cardiovascular disease (DMP number 10)
A DMP conducted in two GP offices focused on im-
proving care for those with an elevated risk of cardio-
vascular disease. The project team consisted of two
GP-researchers (one of which served as a part-time
project leader) and a nurse manager, who did the day-to-management of the program and study. As written in
the grant proposal, the key elements of the program were:
a) a patient choice program to promote a commitment
to the formulated treatment goals
b) a focus on reaching people with a low socio-economic
status (SES)
c) the use of a web-based patient record (Grant proposal)
This DMP was a newly formed project, developed by
the project leader who had recently completed a Masters
in Healthcare Management from a nearby university.
Program attributes
The disease management project focused on providing
coordinated care with multiple clinicians to a challen-
ging population: patients with an elevated cardiovascular
risk and a lower SES.
We have many patients, about 20% of the patients in
the GPs practices are known to the GP as having one
form of elevated cardiovascular risk. That’s a very big
number of patients. Of those patients, about 8 or 9%
are under regular control of the GP. And from those, a
small part has a low SES. Especially patients at low
SES do not follow our advice; you can see that as you
look at the numbers. Most people, more people at low
SES, dying of cardiovascular diseases, more people
smoking… That’s the most important start of our
project. And we don’t reach people with low SES, so
we are looking at new methods of treatment of people
with low SES. (Interview 1 with project leader)
The patients with a lower SES were, and commonly are
in healthcare, seen as a tricky population with multiple
problems, less access to resources, and lower rates of liter-
acy. Providing care and self-management education to this
population was expected to be (and was) challenging for
the project leadership team and clinicians, requiring a sig-
nificant time investment. To be overcome, these challenges
required effort on the part of the clinicians, patients, and
project leaders.
Much of the investment of time for project leaders, in
general, comes in the early stages of the DMPs. As time
goes on in the course of programs, project leaders de-
velop a better sense of the population and are better able
to tailor attributes of the DMP for the needs of specific
populations. This was the case in the CVRM program,
as the project leader noted below:
Then we ask the patient, do you want to look at your
own patient file on the internet? And when he says yes,
he can open his own file and see his own cardiovascular
risk profile on the internet. Because we suppose that not
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can look at his file on the internet. So that’s why we ask
this to every patient. (Interview 1 with project leader)
This patient population required (more) time and ef-
fort from project leaders, clinicians, and medical office
staff, as the patient population may not have had inter-
net access, may have spoken limited Dutch, and may
have had fewer economic and social resources for sup-
port. Accommodating this population to ensure good
care required time during the clinical visit and, for the
project leaders, time during the D&I of the DMP.
However, the challenges with the patient population were
not the only challenges that the project leadership faced.
Well, you’ve got to separate the problems: content level
and organizational level. Content, I think, it actually
runs smoothly. We must, of course, continue to
develop, but that is going the way we want.
Organizationally we have some problems. [Primary
care] practices are (…) very large organizations now.
So before we begin, we have to convince everyone of
the importance of the research. That takes a lot of
effort. Plus the implementation of such a project, in
practice is not simple because practices are large
organizations where 30 people work. Plus there are
other members of the care group that need to be
involved: the physiotherapist, the dietician.
(Interview with the project leadership team)
Effort and accommodation, in the form of meetings,
telephone support, and emails, was needed to assist the
clinicians in implementing the changes needed for
implementing a DMP and for conducting research on
the program.
Internet-based communication systems
As was seen in many other projects, the D&I of the net-
worked electronic medical record required much time
and effort over the course of years; this effort included
working with outside vendors, outside educators, and
outside funding agencies, as well as working with clini-
cians and GP office staff. The effort did not stop;
changes and further tailoring continued after the record
was in place. The project leaders and manager were key
in these activities.
And for the development of cardiovascular risk
management, this is how far we are now: we have
funding. We are now working with contract
negotiations. And then we can start developing and
the ICT supplier, if they are fast, can get us a beta
version in three months’ time. We hope that we can
really start with ICT in March, February… well, ofcourse it is a problem to get financing. A negotiation
problem. Yes, but we are happy that we have had
luck. (Interview with the project leadership team)
Because health insurers provided some of the financing
needed for the D&I of the networked electronic medical
record, there was much coordination work needed. Health
insurers required extensive plans, budgets and presenta-
tions before financing was awarded. This was in addition
to the work needed to develop the record, such as working
with the developers and clinicians. Patient portals were in-
cluded in the development of the networked electronic
medical record, allowing patients to go online and access
their record.
You can see here, patients with active risk. This is what
patients can see at home. The treatment goal of this
patient was weight reduction of 6 kg in 3 months.
And you can see at this point, he has reached a risk
reduction of 80% of his goal. … Here is the plan and
what he or she still has to do is treating hypertension
and becoming more adherent for medication. But this
patient has chosen for weight reduction in a first step
for cardiovascular risk treatment. (Interview 1 with
project leader)
While project leaders hoped that the implementation
of clinical information systems would improve care for
those with a chronic illness, the D&I of the system to
this point has come at a significant time–cost in both sites.
As Wears and Berg noted, while electronic medical re-
cords are often thought of as a panacea for the ills of med-
ical documentation, this is often more dream than reality
[14]. To meet the goal of including patients into the pa-
tient portal of the new record system, additional time on
the part of the clinician and of the project leader was
needed, time to tinker with the system, to tailor the system
to the needs of the clinicians and of the individual patient,
who may or may not have had computer access.
Project leadership
For this two-practice project, project leadership took
the form of a team of two GPs and a nurse manager.
The nurse’s duties included interacting directly with
staff at the practices, coordinating the research efforts,
and aiding the practice staff as they adopted disease
management principles. The work of the project leader-
ship team started:
by organizing meetings. That’s why we start with 4
meetings and why we start at practice level. Speak
with the GPs and the nurses. And we have learned to
start slowly, go slowly. I will not tell my GPs to start
with 100 patients but will tell my GPs we will start
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practice. I hope it works. But we have to wait for it
still. (Interview 1 with project leader)
Changing the practice was seen to need to begin
slowly in order to gain support from clinicians and staff
at the two GP offices. The project leader saw this coord-
ination and background work as necessary before large-
scale changes in patient care were implemented. While
this work can be seen as an investment, it was likely a
notable source of D&I costs.
Another significant challenge for the project leader-
ship team was to work to procure additional funding for
the DMP.
Step by step, we write down [the plan] for the
insurance company. Because they will first look at the
plan. After they will decide whether to give us some
money. And when you are going to visit your GP, the
GP will receive 9 Euros. But when you do the visit
according to our rules of cardiovascular risk
management, we think that the consult will take half an
hour so we have asked to the insurance company not 9
Euros but 25 Euros. (Interview 1 with project leader)
The complete implementation of the program goals
cost more time at the patient care level as well as the
time and effort invested at the project leader level to
procure more funding.
Discussion
The findings of this study show that large variation ex-
ists in the D&I costs of DMPs implemented in the
Netherlands. This variation can be explained by the large
variability in DMP development duration, size of DMP
providing organization, and the level of care in the pro-
viding organization prior to the implementation of a
DMP. The qualitative analysis showed that these charac-
teristics were associated with the attributes of the inter-
ventions, project leadership, and the history of the ICT
systems used in a DMP.
The DMP development duration is positively related
to the labor intensiveness during the development phase
and development costs. Considering that the develop-
ment costs are highly positively correlated to the imple-
mentation costs, the length of the development phase is
an important cost driver of D&I costs.
The research on the case studies and other qualitative
research conducted in the remaining 19 sites highlighted
that the D&I of an ICT system was an involved process.
While previous literature shows that a well-developed
ICT system is one of the main preconditions of success-
ful implementation of bundled payments and DMPs in
the Netherlands [6], the work required to develop andimplement ICT systems was, at the sites, time-consuming
and costly. In the diabetes case study, the majority of the
development work involved in implementing the ICT sys-
tem occurred before the study period, but nonetheless the
work did happen; however, the cost for this work is not in-
cluded in the financial data in the diabetes project. As the
ICT work (and the costs associated) was included in the
D&I period of the CVRM project, this may be an explan-
ation for variation in costs. The D&I of adequate ICT is
important for all stakeholders in chronic care. It is import-
ant for care groups with the aim of achieving lower D&I
costs, for health insurers in order to contract chronic care
at lower cost, and for public authorities with the purpose
of controlling healthcare expenditure by supporting man-
aged care for chronic diseases. As our data shows, this
D&I requires time, financial support, and a flexibility of
goals, targets, and timelines, no matter when it occurs or
how the D&I is funded.
The qualitative research conducted at the sites re-
vealed that the role of the project leader was an import-
ant one, with more established projects with experienced
project leaders and managers spending less time on the
early development of the programs. Project leaders were
responsible for guiding the programs, working with cli-
nicians, delegating responsibilities, and developing con-
tacts with outside funders and vendors. In the studied
sites, we saw that in projects with a longer history (and
with a project leader with more experience in leading
healthcare projects and in the DMP project in specific),
the relationships needed for smooth, efficient project
management were likely developed in the early years of
the programs and the costs for these efforts have not
been included in the D&I costs (as was seen in diabetes
project). In the CVRM project, these relationships were
in the process of being developed during the study in an
incremental manner through meetings, developing pro-
ject plans, and the slow introduction of changes. Project
leadership, in general, was especially relevant in that
organizational and management failure threaten the suc-
cessful implementation of disease managed care facili-
tated by bundled payment in the Netherlands [6].
Project leaders had a fluid role and flexibility within the
project, as meeting project goals often requires adaptation.
Whether by offering new tools online or printing for pa-
tients who have limited computer access at home, this
constant adaptation by project leaders and clinicians can
be seen as “persistent tinkering in a world full of complex
ambivalence and shifting tensions” [18]. Through tinker-
ing, project leaders worked to meet the changing needs of
patients, of the healthcare system, and of themselves. Yet
tinkering was a slow and often invisible process, as was
much of the work of project leaders when tailoring inter-
ventions, applying for funding, or working with re-
searchers. This tinkering was constant during the study
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prevalent in the D&I stages as the project leaders are
working with new vendors, systems, and care plans. This
prevalence of tinkering in the early stages of a DMP may
have resulted in higher D&I costs.
The specific DMP populations, too, may have had a
significant impact on the D&I of the DMPs. The CVRM
DMP was working with patients with low SES, many of
whom were reported to be complex patients with limited
access to resources. Accommodating the needs of this
population may have required more tinkering, more ef-
fort from project leaders, and more time from clinicians.
These characteristics could have played a role in the
higher D&I costs for this site.
Our findings also suggest that large organizations pro-
viding DMPs are more likely to have lower D&I costs
than smaller organizations. This indicates the existence
of economies of scope where large organizations may
have already established ICT systems, managerial know-
ledge, and available capital in other care (e.g. public
health and prevention) and disease areas that can be also
used in the development of disease specific DMPs. This
is supported also by the negative relation between the
existing level of disease managed care (as measured by
the PACIC) in the first phase of implementing a DMP
with D&I costs. This unveils existing synergies between
projects within organizations. The economies of scope
may appeal financially attractive to DMP providers since
they might increase the profit margin of providing
DMPs for different diseases. The provision of DMPs that
could address different disease areas and multi-
morbidity could also tackle the criticism of the current
DMPs that they are narrowly focused on a single disease
while chronic patients need broader care because they
often have one or more other diseases (55% of the pa-
tients in our sample have more than one chronic dis-
ease). Such a development could also tackle the
hesitations of health insurers in contracting DMPs.
Moreover, the minor, though negative, relation be-
tween the number of DMP participants and the imple-
mentation costs, as illustrated in Figure 4, may indicate
the presence of economies of scale. The more patients
included in a DMP, the lower the marginal costs of im-
plementation. This can be attributed to fixed costs that
are divided by more DMP participants. Capital and oper-
ating costs, which are included in the implementation
costs, are known cost components subject to economies
of scale. This financial advantage of large organizations
may attract health insurers to purchase DMP from them
hoping for a lower bundled payment per DMP participant.
However, as in all industries, the number of participants
that lowers the marginal costs of DMP implementation
should be investigated because further inclusion can lead
to higher costs.Furthermore, we found no evidence of relation between
D&I costs and DMP payment method. Similar to case
two, many DMPs reported challenges to get additional fi-
nancing for the provision of a DMP. However, this did not
lead in all cases to higher D&I costs. A previous study
found a positive relation between additional funding for
disease managed care and healthcare utilization costs [19].
Therefore, care groups should be careful in setting the
prices of DMPs when negotiating a bundled payment be-
cause that price should cover not only the costs of health-
care for the particular disease but also the D&I costs.
There was also no relation found between D&I costs
and type of disease addressed by a DMP. That suggests
that none of the diseases studied here can be character-
ized as “cherries” or “lemons” in the chronic care market
with respect to D&I costs. This fact may enable the
broadening of the scope of diseases that a DMP ad-
dresses by making every disease equally financial attract-
ive to care groups.
The 22 DMPs are considered to be representative of
the DMPs that have been implemented the last 3 years
in the Netherlands because (a) they cover all diseases for
which DMPs have been implemented, (b) they include
DMPs in primary and/or secondary care (the most com-
mon settings for DMPs), (c) they cover a wide variety of
diverse regions and geographic areas with different
population density and (d) they differ in the attributes of
the DMPs put into place and in the structure of multi-
disciplinary teams [5]. The study population per disease
is also representative of the overall disease population in
the Netherlands with respect to age and gender.
The findings of this study are relevant to primary care
practices in the Netherlands as well as to health policy
makers and primary care practices in other European
countries that have implemented or are planning to imple-
ment DMPs to achieve integration of chronic care. The
programs in this study represent a diversity of chronic dis-
eases that can be addressed by DMPs, ranging from com-
mon chronic diseases such as diabetes, CVRM, and
COPD, to less frequently addressed chronic diseases such
as depression, eating disorders, and mental illnesses. The
programs, while diverse, had features in common with
other DMPs outside of the Netherlands: addressing the is-
sues of chronic illness through coordinated care, through
the use of ICT systems, and through the promotion and
implementation of self-management education. This re-
search also provides unique insights into the role of project
leaders and of the impact of the history of the programs on
D&I costs. Policy makers, DMP designers, and primary care
practices in the Netherlands and in Europe can explore the
possibilities to contain D&I costs at a minimum level by en-
hancing leadership and ICT in DMPs as well as exploit
existing economies of scope and economies of scale in the
provision of DMPs.
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The conclusions of this paper can be summarized into:
 There is wide variation in D&I costs of DMPs,
which is driven primarily by the duration of the
development phase and the labor intensiveness
needed to develop and implement a DMP.
 The level of disease managed care in an organization
prior to the provision of a DMP is negatively
associated with the D&I costs of this DMP.
 Assisting care groups to develop adequate ICT
systems for disease managed care is a win-win
situation for all stakeholders.
 It is crucial to define the right mix of DMP
interventions and target population and to
incorporate these mixes in the planning and
budgeting of the DMP development phase.
 There are indications of existence of economies of
scale and economies of scope, which may reduce
D&I costs. Care groups and health insurers should
explore the potentials in exploiting them in a
mutually benefiting manner.
 The work done before the sites are awarded study
funding, especially in relation to ICT systems, saves
time and money during the program and study.
 The experience of project leaders may play a
fundamental role in the development and early
intervention efforts of the DMP.
 Programs with a longer history, more experienced
project leadership, previously established ICT
systems, and less complex patient populations had
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